Cargando…

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole

BACKGROUND: Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other major global pathogens, Leishmania spp., res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chiung-Kuang, Leung, Siegfried S. F., Guilbert, Christophe, Jacobson, Matthew P., McKerrow, James H., Podust, Larissa M.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850312/ https://www.ncbi.nlm.nih.gov/pubmed/20386598 http://dx.doi.org/10.1371/journal.pntd.0000651

Ejemplares similares

Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
por: Gunatilleke, Shamila S., et al.
Publicado: (2012)

Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit
por: Chen, Chiung-Kuang, et al.
Publicado: (2009)

Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51
por: Vieira, Debora F., et al.
Publicado: (2014)

4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency
por: Calvet, Claudia M., et al.
Publicado: (2014)

Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole
por: Calvet, Claudia Magalhães, et al.
Publicado: (2020)

Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model
por: Dauchy, Frédéric-Antoine, et al.
Publicado: (2016)

Correction: Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model
Publicado: (2017)

Repetitive DNA is associated with centromeric domains in Trypanosoma brucei but not Trypanosoma cruzi
por: Obado, Samson O, et al.
Publicado: (2007)

Overview of DNA Repair in Trypanosoma cruzi, Trypanosoma brucei, and Leishmania major
por: Passos-Silva, Danielle Gomes, et al.
Publicado: (2010)

Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection
por: Engel, Juan C., et al.
Publicado: (1998)

Combination With Tomatidine Improves the Potency of Posaconazole Against Trypanosoma cruzi
por: Rocha-Hasler, Marianne, et al.
Publicado: (2021)

The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion
por: Doyle, Patricia S., et al.
Publicado: (2011)

Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity
por: Franco, Caio H., et al.
Publicado: (2020)

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection
por: Calvet, Claudia Magalhaes, et al.
Publicado: (2017)

Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi
por: Parsons, Marilyn, et al.
Publicado: (2005)

In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi
por: Chen, Yen Ting, et al.
Publicado: (2010)

Hypothemicin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei
por: Nishino, Mari, et al.
Publicado: (2013)

RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease Progression in a Mouse Model
por: Abdulla, Maha-Hamadien, et al.
Publicado: (2008)

Correction: Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei
por: Nishino, Mari, et al.
Publicado: (2013)

SUMOylation in Trypanosoma brucei
por: Klein, Cornelia Andrea, et al.
Publicado: (2013)

Trypanosoma evansi is alike to Trypanosoma brucei brucei in the subcellular localisation of glycolytic enzymes
por: Moreno, S Andrea, et al.
Publicado: (2015)

Genome-wide in silico screen for CCCH-type zinc finger proteins of Trypanosoma brucei, Trypanosoma cruzi and Leishmania major
por: Kramer, Susanne, et al.
Publicado: (2010)

Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi()
por: Jones, Deuan C., et al.
Publicado: (2010)

Evaluation of In Vitro Activity of Essential Oils against Trypanosoma brucei brucei and Trypanosoma evansi
por: Habila, Nathan, et al.
Publicado: (2010)

High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2020)

Trypanosoma brucei and Trypanosoma cruzi DNA Mismatch Repair Proteins Act Differently in the Response to DNA Damage Caused by Oxidative Stress
por: Grazielle-Silva, Viviane, et al.
Publicado: (2020)

Identification of Leucinostatins from Ophiocordyceps sp. as Antiparasitic Agents against Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2022)

Secondary Metabolites from Vietnamese Marine Invertebrates with Activity against Trypanosoma brucei and T. cruzi
por: Thao, Nguyen Phuong, et al.
Publicado: (2014)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Golgi duplication in Trypanosoma brucei
por: He, Cynthia Y., et al.
Publicado: (2004)

Phylogeography and Taxonomy of Trypanosoma brucei
por: Balmer, Oliver, et al.
Publicado: (2011)

The nuclear proteome of Trypanosoma brucei
por: Goos, Carina, et al.
Publicado: (2017)

Signatures of hybridization in Trypanosoma brucei
por: Kay, Christopher, et al.
Publicado: (2022)

Sensibilidad in vitro a benznidazol, nifurtimox y posaconazol de cepas de Trypanosoma cruzi de Paraguay
por: Acosta, Nidia, et al.
Publicado: (2020)

CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM)
por: Debnath, Anjan, et al.
Publicado: (2017)

Route of inoculation influences Trypanosoma congolense and Trypanosoma brucei brucei virulence in Swiss white mice
por: Ndungu, Kariuki, et al.
Publicado: (2019)

Distinct roles for two RAD51-related genes in Trypanosoma brucei antigenic variation
por: Proudfoot, Chris, et al.
Publicado: (2005)

Interactions among Trypanosoma brucei RAD51 paralogues in DNA repair and antigenic variation
por: Dobson, Rachel, et al.
Publicado: (2011)

C-Terminal Mutants of Apolipoprotein L-I Efficiently Kill Both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense
por: Lecordier, Laurence, et al.
Publicado: (2009)

De Novo Genome Assembly Shows Genome Wide Similarity between Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense
por: Sistrom, Mark, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cejiis7gk28dee4dth9eidjhl6